Chronic airway disease
Conditions
Interventions
Placebo group:Q(KYN) Compound Capsule Placebo
Experimental group:Q(KYN) Compound Capsule
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female individuals aged 60 years or above, and willing to be included in the designated age groups (60-69, 70-79, >=80 years old). 2. Voluntary participation in this study, understanding the research procedures, and having signed a written informed consent form. 3. Residing in the community, capable of self-care, judged by the researchers to have a stable overall health condition without severe functional impairment. 4. Possessing basic visual and communication skills, able to understand and cooperate in completing cognitive function assessment scales (such as MoCA). 5. Expected to be able to complete the 2-year research follow-up.
Exclusion criteria
Exclusion criteria: 1. Suffering from severe or unstable clinical diseases, including but not limited to: cardiovascular and cerebrovascular diseases: unstable angina pectoris, myocardial infarction, revascularization surgery or stroke within the past 6 months; NYHA cardiac function classification III or IV. Respiratory system diseases: severe chronic obstructive pulmonary disease (COPD GOLD 3-4 grade), interstitial lung disease or other diseases causing breathing difficulties at rest or requiring long-term oxygen therapy. Liver and kidney dysfunction: ALT or AST > 2 times the upper limit of normal; estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m^2. 2. Diagnosed dementia (such as Alzheimer's disease) or other neurological diseases severely affecting cognitive function (such as Parkinson's disease). 3. Having a history of active malignant tumor in the past 5 years (excluding cured skin basal cell carcinoma or cervical carcinoma in situ). 4. Having gastrointestinal diseases that affect drug absorption (such as inflammatory bowel disease, history of subtotal gastrectomy), or having taken probiotic supplements regularly for more than 1 month before enrollment. 5. Having a known history of allergy to any component of the study product (probiotics, Chinese herbal powder, placebo excipients). 6. Participating in any other interventional clinical research within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Epigenetic age acceleration;Six-minute walk test distance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body composition and metabolism;Blood biomarkers;Pulmonary function;Cognitive function; | — |
Countries
China
Contacts
Public ContactMa Yuan
The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed